低分子量肝素在不稳定型心绞痛和非ST段抬高型心肌梗死治疗中的作用 - Suppr

Suppr

超能文献

The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction.

作者信息

Cohen M

机构信息

Catheterization Lab, Hahnemann University Hospital, Philadelphia, PA 19102-1192, USA.

出版信息

J Thromb Thrombolysis. 2001 Apr;11(2):171-4. doi: 10.1023/a:1011284902244.

DOI:10.1023/a:1011284902244

PMID:11406733

Abstract

摘要

相似文献

The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction.

J Thromb Thrombolysis. 2001 Apr;11(2):171-4. doi: 10.1023/a:1011284902244.

Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction.

Am J Cardiol. 2000 Apr 27;85(8A):2C-9C. doi: 10.1016/s0002-9149(00)00879-1.

Fondaparinux versus enoxaparin in acute coronary syndromes.

N Engl J Med. 2006 Jun 29;354(26):2829; author reply 2830. doi: 10.1056/NEJMc061206.

Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.

Am J Cardiol. 2002 Sep 1;90(5):477-82. doi: 10.1016/s0002-9149(02)02517-1.

[Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].

Med Clin (Barc). 2000 Nov 4;115(15):583-6. doi: 10.1016/s0025-7753(00)71631-9.

New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction.

Curr Cardiol Rep. 2007 Jul;9(4):289-97. doi: 10.1007/BF02938377.

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

Circulation. 1999 Oct 12;100(15):1593-601. doi: 10.1161/01.cir.100.15.1593.

Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.

Am J Cardiol. 2001 Dec 1;88(11):1230-4. doi: 10.1016/s0002-9149(01)02082-3.

Heparin versus placebo for non-ST elevation acute coronary syndromes.

Cochrane Database Syst Rev. 2014 Jun 27;2014(6):CD003462. doi: 10.1002/14651858.CD003462.pub3.

Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations.

Cleve Clin J Med. 2000 Jan;67(1):59-65. doi: 10.3949/ccjm.67.1.59.

引用本文的文献

Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgery.

Anatol J Cardiol. 2015 Nov;15(11):932-7. doi: 10.5152/akd.2014.5723.

Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.

Br J Clin Pharmacol. 2005 Oct;60(4):364-73. doi: 10.1111/j.1365-2125.2005.02452.x.

本文引用的文献

Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first".

J Invasive Cardiol. 2000 Feb;12 Suppl A:1A-5A.

Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.

Int J Cardiol. 1999 Dec 1;71(3):273-81. doi: 10.1016/s0167-5273(99)00171-0.

The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory.

Am Heart J. 1999 Dec;138(6 Pt 2):S577-85. doi: 10.1053/hj.1999.v138.a102299.

Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).

Eur Heart J. 1999 Nov;20(21):1553-62. doi: 10.1053/euhj.1999.1879.

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

Circulation. 1999 Oct 12;100(15):1593-601. doi: 10.1161/01.cir.100.15.1593.

Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.

Lancet. 1999 Aug 28;354(9180):708-15.

Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting.

Am J Cardiol. 1998 Sep 10;82(5B):29L-32L. doi: 10.1016/s0002-9149(98)00110-6.

New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials.

Am Heart J. 1998 Jun;135(6 Pt 3 Su):S343-52. doi: 10.1053/hj.1998.v135.90302.

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].

Circulation. 1998 May 5;97(17):1702-7. doi: 10.1161/01.cir.97.17.1702.

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

N Engl J Med. 1997 Aug 14;337(7):447-52. doi: 10.1056/NEJM199708143370702.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验